Large-plaque mutants of sindbis virus show reduced binding to heparan sulfate, heightened viremia, and slower clearance from the circulation

Journal of Virology

Volumn 74, Issue 2, 2000, Pages 644-651

  Byrnes, Andrew P ^a   Griffin, DianeE ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; HEPARAN SULFATE; HEPARIN BINDING PROTEIN; VIRUS GLYCOPROTEIN;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL MODEL; ARTICLE; CELL STRAIN BHK; ENZYME LINKED IMMUNOSORBENT ASSAY; HALF LIFE TIME; HAMSTER; MALE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; SINDBIS VIRUS; VIREMIA;

ALPHAVIRUS INFECTIONS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; CELL LINE; CHO CELLS; CRICETINAE; HEPARIN; HEPARITIN SULFATE; MALE; MICE; MICE, INBRED ICR; MUTAGENESIS, SITE-DIRECTED; PLAQUE ASSAY; SINDBIS VIRUS; VIRAL ENVELOPE PROTEINS; VIREMIA;

EID: 0033989275     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.2.644-651.2000     Document Type: Article

References (56)

1. Abrahamson, S. L., H.-M. Wu, R. E. Williams, K. Der, N. Ottah, R. Little, H. Gazzano-Santoro, G. Theofan, R. Bauer, S. Leigh, A. Orme, A. H. Horwitz, S. F. Carroll, and R. L. Dedrick. 1997. Biochemical characterization of recombinant fusions of lipopolysaccharide binding protein and bactericidal/ permeability-increasing protein. J. Biol. Chem. 272:2149-2155.
2. Bauer, R. J., K. Der, N. Ottah-Ihejeto, J. Barrientos, and A. H. C. Kung. 1997. The role of liver and kidney on the pharmacokinetics of a recombinant amino terminal fragment of bactericidal/permeability-increasing protein in rats. Pharm. Res. 14:224-229.
3. Bhattacharyya, D., B. R. Brooks, and L. Callahan. 1996. Positioning of positively charged residues in the V3 loop correlates with HIV type 1 syncytium-inducing phenotype. AIDS Res. Hum. Retrovir. 12:83-90.
4. Byrnes, A. P., and D. E. Griffin. 1998. Binding of Sindbis virus to cell surface heparan sulfate. J. Virol. 72:7349-7356.
5. Cahan, L. D., R. Singh, and J. C. Paulson. 1983. Sialyloligosaccharide receptors of binding variants of polyoma virus. Virology 130:281-289.
6. Chen, Y., T. Maguire, R. E, Hileman, J. R. Fromm, J. D. Esko, R. J. Linhardt, and R. M. Marks. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3:866-871.
7. Davis, N. L., N. Powell, G. F. Greenwald, L. V. Willis, B. J. B. Johnson, J. F. Smith, and R. E. Johnston. 1991. Attenuating mutations in the E2 glycoprotein gene of Venezuelan equine encephalitis virus: construction of single and multiple mutants in a full-length cDNA clone. Virology 183:20-31.
8. Diamond, L. 1964. Cell transformation in vitro and tumor induction in vivo by large-and small-plaque polyoma virus. Virology 23:73-80.
9. Dubensky, T. W., R. Freund, C. J. Dawe, and T. L. Benjamin. 1991. Polyomavirus replication in mice: influences of VP1 type and route of inoculation. J. Virol. 65:342-349.
10. Esko, J. D., T. E. Stewart, and W. H. Taylor. 1985. Animal cell mutants defective in glycosaminoglycan biosynthesis. Proc. Natl. Acad. Sci. USA 82:3197-3201.
11. Fry, E. E., S. M. Lea, T. Jackson, J. W. I. Newman, F. M. Ellard, W. E. Blakemore, R. Abu-Ghazaleh, A. Samuel, A. M. Q. King, and D. I. Stuart. 1999. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J. 18:543-554.
12. Gibaldi, M., and D. Perrier. 1975. Pharmacokinetics, p. 45-96. Marcel Dekker, Inc., New York, N.Y.
13. Grieder, F. B., N. L. Davis, J. F. Aronson, P. C. Charles, D. C. Sellon, K. Suzuki, and R. E. Johnston. 1995. Specific restrictions in the progression of Venezuelan equine encephalitis virus-induced disease resulting from single amino acid changes in the glycoproteins. Virology 206:994-1006.
14. Hartmann, G., T. Prospero, V. Brinkmann, Ö. Ozcelik, G. Winter, J. Hepple, S. Batley, F. Bladt, M. Sachs, C. Birchmeier, W. Birchmeier, and E. Gherardi. 1998. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 8:125-134.
15. Hileman, R. E., J. R. Fromm, J. M. Weiler, and R. J. Linhardt. 1998. Glycosaminoglycan-protein interactions: definition of consensus sites in glycosaminoglycan binding proteins. Bioessays 20:156-167.
16. Hsiao, J.-C., C.-S. Chung, and W. Chang. 1998. Cell surface proteoglycans are necessary for A27L protein-mediated cell fusion: identification of the N-terminal region of A27L protein as the glycosaminoglycan-binding domain. J. Virol. 72:8374-8379.
17. Igarashi, T., C. Brown, A. Azadegan, N. Haigwood, D. Dimitrov, M. A. Martin, and R. Shibata. 1999. Human immunodeficiency virus type 1 neutralizing antibodies accelerate clearance of cell-free virions from blood plasma. Nat. Med. 5:211-216.
18. Jackson, T., F. M. Ellard, R. Abu Ghazaleh, S. M. Brookes, W. E. Blakemore, A. H. Corteyn, D. I. Stuart, J. W. I. Newman, and A. M. Q. King. 1996. Efficient infection of cells in culture by type O foot-and-mouth disease virus requires binding to cell surface heparan sulfate. J. Virol. 70:5282-5287.
19. Jahrling, P. B. 1976. Virulence heterogeneity of a predominantly avirulent western equine encephalitis virus population. J. Gen. Virol. 32:121-128.
20. Jahrling, P. B., and L. Gorelkin. 1975. Selective clearance of a benign clone of Venezuelan equine encephalitis virus from hamster plasma by hepatic reticuloendothelial cells. J. Infect. Dis. 132:667-676.
21. Jahrling, P. B., D. E. Hilmas, and C. D. Heard. 1977 Vascular clearance of Venezuelan equine encephalomyelitis viruses as a correlate to virulence for rhesus monkeys. Arch. Virol. 55:161-164.
22. Jahrling, P. B., and W. F. Scherer. 1973. Growth curves and clearance rates of virulent and benign Venezuelan encephalitis viruses in hamsters. Infect. Immun. 8:456-462.
23. Jan, J.-T., A. P. Byrnes, and D. E. Griffin. 1999. Characterization of a Chinese hamster ovary cell line developed by retroviral insertional mutagenesis that is resistant to Sindbis virus infection. J. Virol. 73:4919-4924.
24. 1 Campos. Virology 193:604-613.
25. Ji, Z.-S., D. A. Sanan, and R. W. Mahley. 1995. Intravenous heparinase inhibits remnant lipoprotein clearance from the plasma and uptake by the liver: in vivo role of heparan sulfate proteoglycans. J. Lipid Res. 36:583-592.
26. Joyce, J. G., J. S. Tung, C. T. Przysiecki, J. C. Cook, E. D. Lehman, J. A. Sands, K. U. Jansen, and P. M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274:5810-5822.
27. Karlsson, K., and S. L. Marklund. 1988. Plasma clearance of human extracellular-superoxide dismutase C in rabbits. J. Clin. Investig. 82:762-766.
28. Karlsson, K., J. Sandström, A. Edlund, T. Edlund, and S. L. Marklund. 1993. Pharmacokinetics of extracellular-superoxide dismutase in the vascular system. Free Rad. Biol. Med. 14:185-190.
29. Karlsson, K., J. Sandström, A. Edlund, and S. L. Marklund. 1994. Turnover of extracellular-superoxide dismutase in tissues. Lab. Investig. 70:705-710.
30. Kjellén, L., and U. Lindahl. 1991. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60:443-475.
31. Klimstra, W. B., H. W. Heidner, and R. E. Johnston. 1999. The furin protease cleavage recognition sequence of Sindbis virus PE2 can mediate virion attachment to cell surface heparan sulfate. J. Virol. 73:6299-6306.
32. Klimstra, W. B., K. D. Ryman, and R. E. Johnston. 1998. Adaptation of Sindbis virus to BHK cells selects for use of heparan sulfate as an attachment receptor. J. Virol. 72:7357-7366.
33. Krusat, T., and H.-J. Streckert. 1997. Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Arch. Virol. 142:1247-1254.
34. Li, M.-L., and V. Stollar. 1995. A mutant of Sindbis virus which is released efficiently from cells maintained in low ionic strength medium. Virology 210:237-243.
35. Lyon, M., J. A. Deakin, and J. T. Gallagher. 1994. Liver heparan sulfate structure: a novel molecular design. J. Biol. Chem. 269:11208-11215.
36. Mendoza, Q. P., J. Stanley, and D. E. Griffin. 1988. Monoclonal antibodies to the E1 and E2 glycoproteins of Sindbis virus: definition of epitopes and efficiency of protection from fatal encephalitis. J. Gen. Virol. 70:3015-3022.
37. Olmsled, R. A., W. J. Meyer, and R. E. Johnston. 1986. Characterization of Sindbis virus epitopes important for penetration in cell culture and pathogenesis in animals. Virology 148:245-254.
38. Patel, M., M. Yanagishita, G. Roderiquez, D. C. Bou-Habib, T. Oravecz, B. C. Hascall, and M. A. Norcross. 1993. Cell-surface heparan sulfate proteoglycan mediates HIV-1 infection of T-cell lines. AIDS Res. Hum. Retrovir. 9:167-174.
39. Pence, D. F., N. L. Davis, and R. E. Johnston. 1990. Antigenic and genetic characterization of Sindbis virus monoclonal antibody escape mutants which define a pathogenesis domain on glycoprotein E2. Virology 175:41-49.
40. Postic, B., C. J. Schleupner, J. A. Armstrong, and M. Ho. 1969. Two variants of Sindbis virus which differ in interferon induction and serum clearance. I. The phenomenon. J. Infect. Dis. 120:339-347.
41. Rice, C. M., R. Levis, J. H. Strauss, and H. V. Huang. 1987. Production of infectious RNA transcripts from Sindbis virus cDNA clones: mapping of lethal mutations, rescue of a temperature-sensitive marker, and in vitro mutagenesis to generate defined mutants. J. Virol. 61:3809-3819.
42. Rostand, K. S., and J. D. Esko. 1997. Microbial adherence to and invasion through proteoglycans. Infect. Immun. 65:1-8.
43. Sa-Carvalho, D., E. Rieder, B. Baxt, R. Rodarte, A. Tanuri, and P. W. Mason. 1997. Tissue culture adaptation of foot-and-mouth disease virus selects viruses that bind to heparin and are attenuated in cattle. J. Virol. 71:5115-5123.
44. Strauss, J. H., and E. G. Strauss. 1994. The alphaviruses: gene expression, replication, and evolution. Microbiol. Rev. 58:491-562.
45. Stringer, S. E., and J. T. Gallagher. 1997. Heparan sulphate. Int. J. Biochem. Cell Biol. 29:709-714.
46. Summerford, C., and R. J. Samulski. 1998. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J. Virol. 72:1438-1445.
47. Sutmoller, P., and J. W. McVicar. 1976. Pathogenesis of foot-and-mouth disease: clearance of the virus from the circulation of cattle and goats during experimental viraemia. J. Hyg. 77:245-253.
48. Sutmoller, P., and J. W. McVicar. 1976. Pathogenesis of foot-and-mouth disease: the lung as an additional portal of entry of the virus. J. Hyg. 77:235-243.
49. Takemoto, K. K. 1966. Plaque mutants of animal viruses. Prog. Med. Virol. 8:314-348.
50. Takemoto, K. K., and H. Liebhaber. 1961. Virus-polysaccharide interactions. I. An agar polysaccharide determining plaque morphology of EMC virus. Virology 14:456-462.
51. Ubol, S., B. Levine, S.-H. Lee, N. S. Greenspan, and D. E. Griffin. 1995. Roles of immunoglobulin valency and the heavy-chain constant domain in antibody-mediated downregulation of Sindhis virus replication in persistently infected neurons. J. Virol. 69: 1990-1993.
52. Ugolini, S., I. Mondor, and Q. J. Sattentau. 1999. HIV-1 attachment: another look. Trends Microbiol. 7:144-149.
53. Wells, M. J., and M. A. Blajchman. 1998. In vivo clearance of ternary complexes of vitronectin-thrombin-antithrombin is mediated by hepatic heparan sulfate proteoglycans. J. Biol. Chem. 273:23440-23447.
54. WuDunn, D., and P. G. Spear. 1989. Initial interaction of herpes simplex virus with cells is binding to heparan sulfate. J. Virol. 63:52-58.
55. Yuge, T., A. Furukawa, K. Nakamura, Y. Nagashima, K. Shinozaki, T. Nakamura, and R. Kimura. 1997. Metabolism of the intravenously administered recombinant human basic fibroblast growth factor, trafermin, in liver and kidney: degradation implicated in its selective localization to the fenestrated type microvasculatures. Biol. Pharm. Bull. 20:786-793.
56. Zhang, L., P. J. Dailey, T. He, A. Gettie, S. Bonhoeffer, A. S. Perelson, and D. D. Ho. 1999. Rapid clearance of simian immunodeficiency virus particles from plasma of rhesus macaques. J. Virol. 73:855-860.